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Abstract
Hotspot mutations (c.-124bp G > A and c.-146bp G > A) in the promoter region of the TERT gene have been recently
described in several types of solid tumors, including glioma, bladder, thyroid, liver and skin neoplasms. However,
knowledge with respect to colorectal precursor lesions and cancer is scarce. In the present study we aimed to deter-
mine the frequency of hotspot TERT promoter mutations in 145 Brazilian patients, including 103 subjects with pre-
cursor lesions and 42 with colorectal carcinomas, and we associated the presence of such mutations with the
patients clinical-pathological features. The mutation analysis was conclusive in 123 cases, and none of the precursor
and colorectal carcinoma cases showed TERT promoter mutations. We conclude that TERT mutations are not a
driving factor in colorectal carcinogenesis.
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Colorectal cancer (CRC) is the third most frequent
type of cancer worldwide (Ferlay et al., 2015). This sce-
nario shows the importance to improve strategies for CRC
prevention and early detection to decrease its incidence and
mortality (Goss et al., 2013). CRC arises from a stepwise
evolution of normal mucosa to precursor lesions and ulti-
mately to a malignant tumor. The adenoma is the most
commonly reported precursor lesion of CRC (Fearon and
Vogelstein, 1990; Lieberman et al., 2000). However, alter-
native precursor lesions include the serrated polyp, which
was recently described as a precursor lesion of CRC. Ser-
rated polyps are known to be a heterogeneous group of
colorectal lesions that include hyperplasic polyps (HPs),
sessile serrated adenoma (SSA), traditional serrated ade-
noma (TSA) and mixed polyps. Clinically, HPs are the
most common precursor serrated lesions of CRC (Yamane
et al., 2014). Serrated adenocarcinomas accounts for about
10% of all CRCs (Makinen, 2007).
The classic genetic model for colorectal tumorige-
nesis is driven by the progressive accumulation of a series
of critical mutations in cancer-related genes, such as APC
and KRAS (Fearon and Vogelstein, 1990). Since the molec-
ular alterations among serrated pathways are less under-
stood, the BRAF gene has now emerged as a prevalent
marker in this pathway (Yamane et al., 2014). With the
presence of these genetic alterations, molecular biomarkers
have been widely proposed as a means of CRC screening
and prevention (Imperiale and Ransohoff, 2010).
Recently, hotspot somatic mutations in the TERT pro-
moter region (c.-124bp G > A and c.-146bp G > A) have
been described in several tumors, particularly skin, brain,
thyroid and bladder cancers (Horn et al., 2013; Huang et
al., 2013; Killela et al., 2013; Vinagre et al., 2013; Heiden-
reich et al., 2014). The TERT gene encodes a telomerase re-
verse transcriptase, an essential protein for preserving
telomere genomic integrity. These mutations result in the
creation of new binding motif sites (GGAA) for ETS tran-
scription factors, leading to an increase in TERT activity
and subsequent telomere preservation (Horn et al., 2013;
Huang et al., 2013). Additionally, these hotspot mutations
have been associated with advanced tumor stages and poor
prognosis for patients (Killela et al., 2013; Vinagre et al.,
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2013; Heidenreich et al., 2014). Currently, only one study
evaluated TERT mutation frequency in CRC, and no muta-
tions were found in colorectal adenocarcinomas (Killela et
al., 2013).
Herein, we investigated the frequency of TERT muta-
tions in a series of Brazilian patients with colorectal precur-
sor and cancer lesions. We analyzed 145 Brazilian patients
from the Barretos Cancer Hospital. The clinico-patholo-
gical and molecular features of the patients were previously
reported (Table 1) (Yamane et al., 2014). All included pa-
tients were over 50 years old, with a mean age of 66 years
(ranging from 51 – 89), with similar frequency for both
genders. Patients with known family history, hereditary
CRC, or bowel inflammatory disease were excluded. All
cases were reviewed by an expert pathologist and catego-
rized according to the WHO classification. Tumor DNA
was isolated from formalin-fixed paraffin-embedded
(FFPE) tumor tissue, as previously reported (Yamane et al.,
2014). TERT promoter mutations were identified by PCR
followed by direct sequencing as described elsewhere
(Vinagre et al., 2013; Batista et al., 2016).
Of the 145 samples analyzed, 22 were inconclusive
due to poor quality/quantity of DNA. The evaluation of
hotspot TERT promoter mutations showed that all precur-
sor and cancer lesions (123 samples), which included 45
adenoma polyps, 15 serrated polyps, 22 hyperplastic pol-
yps and 41 adenocarcinomas, were wild-type (Figure 1).
Our results are in agreement with a previous report that
showed the absence of TERT promoter mutation in colo-
rectal adenocarcinomas (Killela et al., 2013). We also
showed for the first time, that these mutations are absent in
precursor lesions as well. Furthermore, it is the first study to
analyze the TERT mutation status in Brazilian colorectal
disease patients.
Telomere length is a major tumor hallmark (Hei-
denreich et al., 2014). Besides hotspot TERT promoter mu-
tations, other pathways are involved with an increase in
telomere length (Heidenreich et al., 2014). One such mech-
anism is the alternative lengthening of telomeres (ATL)
(Cesare and Reddel, 2010; Killela et al., 2013). However, a
previous study reported the absence this pathway in CRC
(Heaphy et al., 2011). Therefore, the mechanisms of telo-
mere length variation in colorectal tumors are still un-
known.
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Figure 1 - Electropherogram of TERT showing the wild-type sequence for both hotspot mutation regions. The arrows indicate the hotspot mutation re-
gions (-124bp and -146bp).
Table 1 - Clinicopathological and molecular features of all patients.
Variables N %
Age 66.0 y mean (range
51- 89)
145 -
Gender Female 71 49.0
Male 74 51.0
Histology Adenocarcinoma 42 29.0
Adenoma polyps 50 34.5
Serrated polyps 15 10.3
Hyperplastic polyps 38 26.2
Precursor Lesion Location Right colon 39 37.9
Left colon 64 62.1
Carcinoma Location Right colon 24 57.1
Left colon 18 42.9
Precursor Lesion Morphology Polypoid 83 81.4
Non polypoid 19 18.6
Precursor Lesion Size (mm) < 10 91 90.1
 10 10 9.9
Precursor Lesion MSI Status MSS 96 96.0
MSI-L 4 4.0
MSI-H 0 0.0
Carcinoma MSI Status MSS 35 83.3
MSI-L 2 4.8
MSI-H 5 11.9
Precursor Lesion KRAS Status MUT 14 13.6
WT 89 86.4
Precursor Lesion BRAF Status MUT 9 8.7
WT 94 91.3
Carcinoma KRAS Status MUT 20 47.6
WT 22 52.4
Carcinoma BRAF Status MUT 2 4.8
WT 40 95.2
MUT, mutated; WT, wild type; MSI-L, microsatellite instability low;
MSI-H, microsatellite instability high; MSS, microsatellite stability.
Concluding, we analyzed for the first time the pres-
ence of TERT promoter mutations in precursor and carci-
noma colorectal lesions in Brazilian patients. The results
showed the lack of TERT promoter mutations, suggesting
that these alterations are not involved in CRC carcino-
genesis.
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